Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma.
Alhaj Moustafa M, Parrondo R, Abdulazeez MF, Roy V, Sher T, Alegria VR, Warsame RM, Fonseca R, Rasheed A, Gonsalves WI, Kourelis T, Kapoor P, Buadi FK, Dingli D, Hayman SR, Reeder CB, Chanan-Khan AA, Ailawadhi S.
Alhaj Moustafa M, et al. Among authors: sher t.
Anticancer Drugs. 2024 Jan 1;35(1):63-69. doi: 10.1097/CAD.0000000000001520. Epub 2023 Apr 6.
Anticancer Drugs. 2024.
PMID: 37067996